JP MORGAN/CALL/BRISTOL-MYERS SQUIBB/50/0.1/20.09.24 | Market Closed - Börse Stuttgart 12:51:12 01/07/2024 pm IST | ||
| 0.029 EUR | +20.83% |
|
| 1 month | +20.83% | ||
| 3 months | -94.08% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 01/24/01 | 0.029 | +20.83% |
| 28/24/28 | 0.024 | -17.24% |
| 27/24/27 | 0.029 | +7.41% |
| 26/24/26 | 0.027 | +3.85% |
| 25/24/25 | 0.026 | -10.34% |
Delayed Quote Börse Stuttgart
Last update July 01, 2024 at 12:51 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | J.P. Morgan |
| WKN | JK0RMN |
| ISIN | DE000JK0RMN8 |
| Date issued | 17/01/2024 |
| Strike | 50 $ |
| Maturity | 20/09/2024 (81 Days) |
| Parity | 10 : 1 |
| Emission price | 0.44 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.6 € |
|---|---|
| Lowest since issue | 0.021 € |
| Spread | 0.01 € |
| Spread % | 34.48% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.3
USD
Average target price
53.19
USD
Spread / Average Target
+28.80%
- Stock Market
- Warrants
- Warrant
